Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine

BMC Infectious Diseases

Dominique A Caugant²  Marc LaForce⁴  Thomas A Clark³  Jennifer Dolan Thomas³  Denis Kandolo⁵  Fabien Diomandé³  Lassana Sangaré¹  Rasmata Ouédraogo⁹  Abdoul-Salam Ouédraogo⁷  Idrissa Sanou¹  Absatou Ky Ba⁶  Paul A Kristiansen⁸ 

[1]Centre Hospitalier Universitaire Yalgado, Ouagadougou, Burkina Faso

[2]Faculty of Medicine, University of Oslo, Oslo, Norway

[3]Centers for Disease Control and Prevention, Atlanta, USA

[4]Meningitis Vaccine Project, Ferney, France

[5]WHO Inter Country Support Team, Ouagadougou, Burkina Faso

[6]Laboratoire National de Santé Public, Ouagadougou, Burkina Faso

[7]Centre Hospitalier Universitaire Souro Sanou, Bobo-Dioulasso, Burkina Faso

[8]Norwegian Institute of Public Health, Oslo, Norway

[9]Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle Ouagadougou, Ouagadougou, Burkina Faso

关键词: Meningitis belt;    MLST;    Conjugate vaccine;    Burkina Faso;    Meningitis;    Carriage;    Neisseria meningitidis;   

Others  :  1146503
DOI  :  10.1186/1471-2334-13-363

 received in 2013-03-07, accepted in 2013-07-12,  发布年份 2013

【 摘 要 】

Background

The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of the 1-29-year-olds in Burkina Faso in 2010. The aim of this study was to genetically characterize meningococcal isolates circulating in Burkina Faso before and up to 13 months after MenAfriVac mass vaccination.

Methods

A total of 1,659 meningococcal carriage isolates were collected in a repeated cross-sectional carriage study of the 1-29-year-olds in three districts of Burkina Faso in 2010 and 2011, before and up to 13 months after mass vaccination. Forty-two invasive isolates were collected through the national surveillance in Burkina Faso in the same period. All the invasive isolates and 817 carriage isolates were characterized by serogroup, multilocus sequence typing and porA-fetA sequencing.

Results

Seven serogroup A isolates were identified, six in 2010, before vaccination (4 from carriers and 2 from patients), and one in 2011 from an unvaccinated patient; all were assigned to sequence type (ST)-2859 of the ST-5 clonal complex. No NmA carriage isolate and no ST-2859 isolate with another capsule were identified after vaccination. Serogroup X carriage and disease prevalence increased before vaccine introduction, due to the expansion of ST-181, which comprised 48.5% of all the characterized carriage isolates. The hypervirulent serogroup W ST-11 clone that was responsible for most of meningococcal disease in 2011 and 2012 was not observed in 2010; it appeared during the epidemic season of 2011, when it represented 40.6% of the serogroup W carriage isolates.

Conclusions

Successive clonal waves of ST-181 and ST-11 may explain the changing epidemiology in Burkina Faso after the virtual disappearance of NmA disease and carriage. No ST-2859 strain of any serogroup was found after vaccination, suggesting that capsule switching of ST-2859 did not occur, at least not during the first 13 months after vaccination.

【 授权许可】

   
2013 Kristiansen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lapeyssonnie L: La méningite cérébrospinale en Afrique [in French]. Bull World Health Organ 1963, 28(Suppl):3-114.
• [2]Molesworth AM, Thomson MC, Connor SJ, Cresswell MP, Morse AP, Shears P, et al.: Where is the Meningitis Belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002, 96:242-249.
• [3]Harrison LH, Trotter CL, Ramsay ME: Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl):B51-B63.
• [4]Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA: Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005, 43:5129-5135.
• [5]Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouédraogo R, et al.: Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012, 7:e46019.
• [6]Nicolas P, Decousset L, Riglet V, Castelli P, Stor R, Blanchet G: Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001, 7:849-854.
• [7]Nicolas P, Ait MN, Al-Awaidy S, Al BS, Sulaiman N, Issa M, et al.: Pharyngeal carriage of serogroup W135 Neisseria meningitidis in Hajjees and their family contacts in Morocco, Oman and Sudan. APMIS 2005, 113:182-186.
• [8]Koumaré B, Ouedraogo-Traoré R, Sanou I, Yada AA, Sow I, Lusamba PS, et al.: The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007, 25(suppl):A37-A41.
• [9]Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, et al.: Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007, 13:920-923.
• [10]Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al.: Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185:1596-1605.
• [11]Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, Mainassara HB, et al.: Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663.
• [12]Nicolas P, Djibo S, Sidikou F, Tenebray B, Stor R, Boisier P, et al.: Epidemics caused by group X meningoccal meningitis in Africa in 2006. Med Trop (Mars) 2006, 66:494.
• [13]Delrieu I, Yaro S, Tamekloe TAS, Njanpop-Lafourcade B-M, Tall H, Jaillard P, et al.: Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011, 6:e19513.
• [14]World Health Organization: Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. WHO/EMC/BAC/98 3 1998; 1998. Available at: http://www.searo.who.int/entity/emergencies/documents/who-meningitis-guidelines.pdf webcite. Accessed 31 July 2013.
• [15]World Health Organization: International Coordinating Group on VaccineProvision for Epidemic Meningitis Control (ICG). Guidelines for applying to the emergency stockpile. WHO Offset Publ 2008. Available at: https://extranet.who.int/aim_elearning/en/vaccines/mening/pdf/ICG_guidelines_2008_02_09.pdf webcite. Accessed 31 July 2013.
• [16]Dellicour S, Greenwood B: Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007, 12:1409-1421.
• [17]LaForce FM, Okwo-Bele J-M: Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
• [18]Frasch CE, Preziosi MP, LaForce FM: Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 2012, 8:715-724.
• [19]Hirve SS, Bavdekar AN, Pandit AN, Juvekar SK, Patil M, Preziosi MP, et al.: Safety and immunogenicity of a new meningococcal A conjugate vaccine in healthy Indian children aged 2–10 years. 16th International Pathogenic Neisseria Conference 2008, P227:285-286.
• [20]Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al.: Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
• [21]Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, et al.: Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(Suppl):B40-B45.
• [22]Kristiansen PA, Diomandé F, Absatou KB, Sanou I, Ouédraogo AS, Ouédraogo R, et al.: Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56:354-363.
• [23]Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, et al.: Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764.
• [24]Musher DM: Pneumococcal vaccine - direct and indirect (herd) effects. N Engl J Med 2006, 354:1522-1524.
• [25]Tsang R: Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect Dis 2007, 7:569-570.
• [26]Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E: No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006, 6:616-617.
• [27]Long SS: Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005, 41:30-34.
• [28]Alcalá B, Arreaza L, Salcedo C, Uría MJ, De La Fuente LD, Vázquez JA: Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis 2002, 8:1512-1514.
• [29]Lancellotti M, Guiyoule A, Ruckly C, Hong E, Alonso JM, Taha MK: Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 2006, 8:191-196.
• [30]Simoes MJ, Cunha M, Almeida F, Furtado C, Brum L: Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002–2006. Epidemiol Infect 2009, 137:161-165.
• [31]Wang Q, Shao Z, Wang X, Gao Y, Li M, Xu L, et al.: Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains. Infect Immun 2010, 78:3883-3888.
• [32]Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, et al.: Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era - United States, 2000–2005. J Infect Dis 2010, 201:1208-1224.
• [33]Snape M, Pollard A: No evidence for capsule replacement…and Wales - authors' reply. Lancet Infect Dis 2006, 6:617-618.
• [34]Kristiansen PA, Diomande F, Wei SC, Ouedraogo R, Sangare L, Sanou I, et al.: Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011, 18:435-443.
• [35]Ajello GW, Feeley JC, Hayes PS: Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. J Clin Microbiol 1984, 1984:20.
• [36]Taha M-K: Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis. J Clin Microbiol 2000, 38:855-857.
• [37]Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al.: Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998, 95:3140-3145.
• [38]Russell JE, Jolley KA, Feavers IM, Maiden MCJ, Suker J: PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10:674-678.
• [39]Thompson EAL, Feavers IM, Maiden MCJ: Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149:1849-1858.
• [40]Caugant DA, Hoiby EA, Froholm LO, Brandtzaeg P: Polymerase chain reaction for case ascertainment of meningococcal meningitis: application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis 1996, 28:149-153.
• [41]WHO Inter country Support Team - WestAfrica: WHO Meningitis Weekly Bulletin. 2013. Available at: http://www.who.int/csr/disease/meningococcal/epidemiological/en webcite. Accessed 20 June 2013
• [42]Djingarey M, Kandolo D, Lingani C, Diomandé F, Medah I, Kambou JL, et al.: Evaluation of meningitis surveillance before introduction of serogroup A meningococcal conjugate vaccine - Burkina Faso and Mali. Wkly Epidemiol Rec 2012, 61:1025-1028.
• [43]Caugant DA, Fogg C, Bajunirwe F, Piola P, Twesigye R, Mutebi F, et al.: Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda. Trans R Soc Trop Med Hyg 2006, 100:1159-1163.
• [44]Mueller JE, Sangare L, Njanpop-Lafourcade BM, Tarnagda Z, Traore Y, Yaro S, et al.: Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg Infect Dis 2007, 13:847-854.
• [45]Nicolas P, Djibo S, Tenebray B, Castelli P, Stor R, Hamidou AA, et al.: Populations of pharyngeal meningococci in Niger. Vaccine 2007, 25(suppl):A53-A57.
• [46]Caugant DA, Tzanakaki G, Kriz P: Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007, 31:52-63.
• [47]Guindo I, Coulibaly A, Dao S, Traoré S, Diarra S, Bougoudogo F: Clones des souches de Neisseria meningitidis au Mali (in French). Med Mal Infect 2011, 41:7-13.
• [48]Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, Smith T, et al.: Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 2007, 4:e101.
• [49]Beddek AJ, Li MS, Kroll JS, Jordan TW, Martin DR: Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun 2009, 77:2989-2994.